EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

Cost-effectiveness of pramipexole in addition to mood stabilisers for patients with treatment-resistant bipolar depression: Economic evaluation of the PAX-BD randomised controlled trial

Michael Berger, Timea Helter, Lumbini Azim, Thomas Chadwick, Paul Courtney, Tony Fouweather, John Geddes, Paul Hindmarch, Richard Morriss, Paul R A Stokes, Stuart Watson, Christopher Weetman und 3 weitere

Journal of Affective Disorders · 2025

DOI: 10.1016/j.jad.2025.119937 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Journal of Affective Disorders, 2025. Verfasst von Michael Berger und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Health Economics, Center for Public Health, Medical University of Vienna, Vienna, Austria. Hauptthemen laut MEDLINE: Pramipexole, Bipolar Disorder, Cost-Benefit Analysis, Depressive Disorder, Treatment-Resistant. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: People with bipolar disorders (BD) frequently experience depressive symptoms that do not respond to available treatment options. The resulting burden for people with BD and society is substantial. This study sought to explore the cost-effectiveness of pramipexole in combination with mood stabilisers for people with treatment-resistant bipolar disorder (TRBD). METHODS: We calculated mean incremental cost-effectiveness ratios (ICER) of pramipexole compared to placebo over 12 and 48 weeks from health and social care (NHS + PSS) and societal perspectives for 36 participants with TRBD. Quality-adjusted life years (QALY) were captured with the EQ-5D-5L as the primary outcome measure. We used capability well-being measures (ICECAP-A, OxCAP-MH) to assess the robustness of the results and multiple imputation and bootstrapping to address missing data and small sample size. RESULTS: We found that pramipexole is dominantly more effective and cost-saving from the NHS + PSS perspective with 86 % probability of being cost-effective at £30,000/QALY gained over 12 weeks and 93 % over 48 weeks. From the societal perspective, pramipexole was more effective but also more expensive with lower probability of cost-effectiveness (36 % over 12 weeks and 48 % over 48 weeks). Uncertainty around the mean ICERs was substantial due to the small sample size. LIMITATIONS: The PAX-BD trial was conducted during the COVID-19 pandemic and terminated early, resulting in a limited generalizability of resource use outside the pandemic context and a small sample size. CONCLUSIONS: Pramipexole is a cost-effective treatment option for TRBD from the NHS + PSS perspective, with statistically significant increases in health-related quality of life and capability well-being over extended periods.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PramipexoleBipolar DisorderCost-Benefit AnalysisDepressive Disorder, Treatment-ResistantAntimanic AgentsHumansMaleFemaleAdultMiddle AgedQuality-Adjusted Life YearsDrug Therapy, Combination

Stichwörter der Autor:innen

Bipolar disorderCost-effectivenessHealth economic evaluationPramipexoleTreatment-resistant bipolar disorder

Substanzen

PramipexoleAntimanic Agents

Autor:innen und Institutionen

  • Department of Health Economics, Center for Public Health, Medical University of Vienna, Vienna, Austria.
  • Cumbria, Northumberland, Tyne and Wear NHS Foundation Trust, Newcastle upon Tyne, UK.
  • Population Health Sciences Institute, Newcastle University, Newcastle upon Tyne, UK.
  • Department of Psychiatry University of Oxford, United Kingdom.
  • Academic Unit of Mental Health and Neuroscience, University of Nottingham, UK.
  • Centre for Affective Disorders, Department of Psychological Medicine, Institute of Psychiatry, Psychology and Neuroscience, King's College London, UK.

Zitieren

APA

Berger, M., Helter, T., Azim, L., Chadwick, T., Courtney, P., Fouweather, T., Geddes, J., Hindmarch, P., Morriss, R., Stokes, P. R. A., Watson, S., Weetman, C., Young, A. H., McAllister-Williams, R. H., & Simon, J. (2025). Cost-effectiveness of pramipexole in addition to mood stabilisers for patients with treatment-resistant bipolar depression: Economic evaluation of the PAX-BD randomised controlled trial. Journal of Affective Disorders. https://doi.org/10.1016/j.jad.2025.119937

Vancouver

Berger M, Helter T, Azim L, Chadwick T, Courtney P, Fouweather T, et al. Cost-effectiveness of pramipexole in addition to mood stabilisers for patients with treatment-resistant bipolar depression: Economic evaluation of the PAX-BD randomised controlled trial. Journal of Affective Disorders. 2025. doi:10.1016/j.jad.2025.119937

BibTeX
@article{Berger2025,
  author = {Berger, Michael and Helter, Timea and Azim, Lumbini and Chadwick, Thomas and Courtney, Paul and Fouweather, Tony and Geddes, John and Hindmarch, Paul and Morriss, Richard and Stokes, Paul R A and Watson, Stuart and Weetman, Christopher and Young, Allan H and McAllister-Williams, R Hamish and Simon, Judit},
  title = {Cost-effectiveness of pramipexole in addition to mood stabilisers for patients with treatment-resistant bipolar depression: Economic evaluation of the PAX-BD randomised controlled trial},
  journal = {Journal of Affective Disorders},
  year = {2025},
  doi = {10.1016/j.jad.2025.119937}
}
Kostenlos starten →